Search
for
Sort by
Research 91–120 of 1000+
- Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
- Jagged1 and Epidermal Growth Factor Promoted Androgen-Suppressed Mouse Hair Growth In Vitro and In Vivo
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
- Lentivirus‐mediated subcutaneous JAM‐A modification promotes skin wound healing in a mouse model by strengthening the secretory function and proliferation of fibroblasts
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- A review of Janus kinase inhibitor use in scarring alopecia
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata
- At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors
- [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Evaluating dermatologists’ knowledge of and attitudes toward Janus kinase inhibitor therapy for the treatment of alopecia areata
- Real-world experience quantifying access to JAK inhibitor care for alopecia areata patients: a patient-centered survey study
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
- Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
- Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice